What’s new

• Aruna Ganesh sold all 1,71,14,604 equity shares (3.05% of equity) on June 18.
• She remains a promoter group member but now holds no direct shares.
• The sale is material given Anthem's ₹44,771 cr market cap.

Why it matters

A promoter group member exiting her entire direct stake is a strong insider-signal event. While Ms. Ganesh stays in the promoter group, the complete sell-off reduces insider alignment for a company trading at 75.7x trailing earnings. For a mid-cap CDMO with ambitious ₹1,200 cr capex plans, this could test investor confidence.

What we’re watching

• Whether other promoter group members follow suit or consolidate.
• Any subsequent open market purchases by the company or other promoters.
• Stock price reaction in the coming sessions given the materiality.

The full read

Aruna Ganesh, a promoter group member, sold her entire direct stake of 1,71,14,604 shares (3.05% of equity) on June 18, 2026. She remains in the promoter group but now holds zero direct shares. For a ₹44,771 cr CDMO trading at 75.7x trailing earnings, this is a material insider offload. The company recently announced a ₹1,200 cr investment in a GLP-1 plant, and its latest quarterly sales were ₹611 cr with net profit of ₹190 cr. The sale could signal reduced personal conviction, even if Ms. Ganesh's promoter tag stays. That's a risk for a stock already pricing in aggressive growth.

Primary source: BSE · NSE

What’s new

• Quarterly revenue hit a record ₹611 cr.
• Capex of ₹1,200 cr will double custom synthesis capacity by March 2028.
• GLP-1 products target the Indian market within 6-8 months.

Why it matters

The company is tying its future to the GLP-1 wave by adding substantial capacity. With 10 Phase 3 molecules now in its pipeline, the firm is shifting from a simple service provider to a late-stage manufacturing partner.

What we’re watching

• Commercialization timeline for the GLP-1 active ingredient.
• Formulator approval status for new products.
• Actual EBITDA conversion as capacity expansion scales.

The full read

Anthem Biosciences just posted record quarterly revenue of ₹611 crore. It is not slowing down.

Management committed ₹1,200 crore to expand its Unit 4 facility, which aims to double custom synthesis capacity by March 2028. The strategy hinges on the Indian GLP-1 market, where the company expects to launch its active ingredient within the next 6-8 months, pending necessary formulator approvals. Beyond this immediate push, the pipeline has reached 10 Phase 3 molecules. While management held back on explicit FY27 guidance, they are targeting long-term growth of 20% across key profit and revenue metrics. Anthem is moving fast; the next test is whether those regulatory approvals arrive on the expected 6-8 month schedule. With a major capex cycle underway, the company has clearly pivoted toward scaling its late-stage pharmaceutical manufacturing footprint to capture share in the high-demand, high-complexity drug market.

Primary source: BSE · NSE